The publication of this podcast was funded by QIAGEN.

Tune in to our latest podcast for valuable insights on non-small cell lung cancer (NSCLC). Esteemed contributors to this discussion include Terri Conneran, a Patient Advocate and founder of KRAS Kickers, and Colin Lindsay, a Clinical Senior Lecturer and Honorary Consultant in Thoracic Medical Oncology at The Christie in Manchester, UK. Both experts underscore the pivotal importance of biomarkers, diagnostic technologies, and collaborative efforts in enhancing survivorship.

During this episode, you'll hear about the need for early biomarker testing in NSCLC, along with a forward-looking exploration of the field's future. Lindsay offers an overview of the current treatment landscape for NSCLC, shedding light on issues like late diagnosis and targeted therapies, as well as outlining next-generation sequencing and liquid biopsy as tools to enhance NSCLC testing. Patient experiences are explored, with Conneran sharing her personal journey with diagnosis and treatment.

Speaker Bios:

Terri Conneran – Patient Advocate and Founder of KRAS Kickers, Charlotte, North Carolina. United States.

Colin Lindsay - Clinical Senior Lecturer and Honorary Consultant in Thoracic Medical Oncology at The Christie, Manchester